Skip to contentT
TuHURA Biosciences, Inc.
T
HURATuHURA Biosciences, Inc. Q3 2025 · 10-Q
Revenue$0.00$0.00derived— vs Q3 2024 Net Income-$7.10M-$7.10MN/M vs Q3 2024 EPS Diluted-$0.14-$0.14N/M vs Q3 2024 Operating Cash Flowderived-$11,086,544N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TuHURA Biosciences, Inc. · CIK 1498382 · Engraved from SEC EDGAR
Free Cash Flowderived-$11,086,544N/M ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end